lialda side effects center find lowest prices on medical editor john p cunha do facoeplast reviewed on rx list 872017lialda mesalamine is an antiinflammatory agent used to treat ulcerative colitis proctitis and proctosigmoiditis and also to prevent the symptoms of ulcerative colitis from recurring common side effects of lialda includenauseavomitingstomach crampsdiarrheagasfeversore throatflulike symptomsconstipationheadachedizzinesstired feeling orskin rash contact your doctor if you experience serious side effects of lialda includingsevere stomach painfeverheadache andbloody diarrhea the recommended dosage of lialda for the induction of remission in adult patients with active mild to moderate ulcerative colitis is two to four 12 g tablets taken once daily with a meal for a total daily dose of 24 g or 48 g the recommended dosage for the maintenance of remission is two 12 g tablets taken once daily with a meal for a total daily dose of 24 g lialda may interact with azathioprine or mercaptopurine pentamidine tacrolimus amphotericin b antibiotics antiviral medicines cancer medicine aspirin or other nsaids tell your doctor all medications you are taking lialda is not expected to be harmful to a fetus tell your doctor if you are pregnant or plan to become pregnant during treatment this medication can pass into breast milk and may harm a nursing baby do not use this medication if you are breastfeeding our lialda mesalamine side effects drug center provides a comprehensive view of available drug information on the potential side effects when taking this medication this is not a complete list of side effects and others may occur call your doctor for medical advice about side effects you may report side effects to fda at 1800fda1088 ulcerative colitis slideshow pictures inflammatory bowel disease slideshow pictures take the ulcerative colitis quiz lialda consumer information get emergency medical help if you have any of these signs of an allergic reaction hives difficulty breathing swelling of your face lips tongue or throat stop taking mesalamine and call your doctor at once if you have a serious side effect such assevere stomach pain cramping fever headache and bloody diarrhea less serious side effects may includemild nausea vomiting stomach cramps diarrhea gasfever sore throat or other flu symptomsconstipationheadache or dizzinesstired feeling orskin rash this is not a complete list of side effects and others may occur call your doctor for medical advice about side effects you may report side effects to fda at 1800fda1088 read the entire detailed patient monograph for lialda mesalaminelearn more »ulcerative colitis slideshow pictures inflammatory bowel disease slideshow pictures take the ulcerative colitis quiz lialda professional information side effectsthe most serious adverse reactions seen in lialda clinical trials or with other products that contain or are metabolized to mesalamine are renal impairment including renal failure see warnings and precautionsmesalamineinduced acute intolerance syndrome see warnings and precautionshypersensitivity reactions see warnings and precautionshepatic impairment including hepatic failure see warnings and precautionsclinical trials experience because clinical trials are conducted under widely varying conditions adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice lialda has been evaluated in 1368 ulcerative colitis patients in controlled and openlabel trials induction of remission in two 8week placebocontrolled clinical trials involving 535 ulcerative colitis patients 356 received 24 gday or 48 gday lialda tablets and 179 received placebo the most frequent adverse reaction leading to discontinuation from lialda therapy was exacerbation of ulcerative colitis 08 pancreatitis occurred in less than 1 of patients during clinical trials and resulted in discontinuation of therapy with lialda in patients experiencing this event adverse reactions occurring in lialda or placebo groups at a frequency of at least 1 in two 8 week double blind placebocontrolled trials are listed in table 1 the most common adverse reactions with lialda 24 gday and 48 gday were headache 56 and 34 respectively and flatulence 4 and 28 respectively table 1 adverse reactions in two eightweek placebocontrolled trials experienced by at least 1 of the lialda group and at a rate greater than placebo a adverse reaction lialda 24 gday n  177 lialda 48 gday n  179 placebo n  179headache 10 56 6 34 1 06flatulence 7 4 5 28 5 28liver function test abnormal 1 06 4 22 2 11alopecia 0 2 11 0pruritus 1 06 2 11 2 11a adverse reactions for which the placebo rate equalled or exceeded the rate for at least one of the lialda treatment groups were abdominal pain dizziness dyspepsia and nausea the following adverse reactions presented by body system were reported infrequently less than 1 by lialdatreated ulcerative colitis patients in the two controlled trials cardiac disorder tachycardia vascular disorders hypertension hypotension skin and subcutaneous tissue disorders acne prurigo rash urticaria gastrointestinal disorders abdominal distention colitis diarrhea pancreatitis rectal polyp vomiting investigations decreased platelet count musculoskeletal and connective tissue disorders arthralgia back pain nervous system disorders somnolence tremor respiratory thoracic and mediastinal disorders pharyngolaryngeal pain general disorders and administrative site disorders asthenia face edema fatigue pyrexia ear and labyrinth disorders ear pain maintenance of remission of ulcerative colitis the dose evaluated in three studies of lialda given for the maintenance of remission in patients with ulcerative colitis was 12 g twice daily or 24 gonce daily one of these studies was a 6month doubleblind comparator study while two were 12 to 14month openlabel studies the most common adverse reactions with lialda in the maintenance arms of longterm trials were colitis ulcerative 58 headache 29 liver function test abnormal 23 and abdominal pain 22 of the 1082 subjects in the all maintenance studies pooled 19 had severe adverse reactions the most common severe adverse reactions were gastrointestinal disorders these were mainly symptoms associated with ulcerative colitis table 2 adverse reactions in three maintenance trials experienced by at least 1 of the lialda group maintenance phases of trials all lialda n1082adverse reaction n colitis ulcerative 63 58headache 31 29liver function test abnormal 25 23abdominal pain 24 22diarrhea 18 17abdominal distension 14 13abdominal pain upper 13 12dyspepsia 13 12back pain 13 12rash 13 12arthralgia 12 11fatigue 11 10hypertension 10 10the following adverse reactions presented by body system were reported infrequently less than 1 by lialdatreated ulcerative colitis patients in the three longterm maintenance trials maintenance phases of these trials cardiac disorder tachycardia skin and subcutaneous tissue disorders acne alopecia pruritis urticaria gastrointestinal disorders colitis flatulence nausea pancreatitis rectal polyp vomiting nervous system disorders dizziness respiratory thoracic and mediastinal disorders pharyngolaryngeal pain general disorders and administrative site disorders asthenia pyrexia ear and labyrinth disorders ear pain postmarketing experience in addition to the adverse reactions reported above in clinical trials involving lialda the adverse reactions listed below have been identified during postapproval use of lialda and other mesalaminecontaining products because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure body as a whole lupus like syndrome drug fever cardiac disorders pericarditis pericardial effusion myocarditis gastrointestinal pancreatitis cholecystitis gastritis gastroenteritis gastrointestinal bleeding perforated peptic ulcer hepatic jaundice cholestatic jaundice hepatitis liver necrosis liver failure kawasakilike syndrome including changes in liver enzymes hematologic agranulocytosis aplastic anemia immune system disorders anaphylactic reaction angioedema stevensjohnson syndrome  sjs  drug reaction with eosinophilia and systemic symptoms dressmusculoskeletal and connective tissue disorders myalgia neurologicalpsychiatric peripheral neuropathy guillainbarre syndrome transverse myelitis  intracranial hypertension renal disorders interstitial nephritis nephrogenic diabetes insipidus respiratory thoracic and mediastinal disorders hypersensitivity pneumonitis including interstitial pneumonitis allergic alveolitis eosinophilic pneumonitisskin psoriasis pyoderma gangrenosum erythema nodosum urogenital reversible oligospermia descriptions of selected adverse reactions intracranial hypertension cases of intracranial hypertension increased intracranial pressure with papilledema pseudotumor cerebri or benign intracranial hypertension have been reported with mesalamine use if undetected this condition may result in constriction of the visual field and permanent vision loss mesalamine should be discontinued if clinically possible if this syndrome occurs nephrogenic diabetes insipidus cases of nephrogenic diabetes insipidus have been reported with mesalamine use read the entire fda prescribing information for lialda mesalamineread more »ulcerative colitis slideshow pictures inflammatory bowel disease slideshow pictures take the ulcerative colitis quiz related resources for lialda related health ulcerative colitis related drugs asacol asacol hdazulfidine colazal cortenema delzicol dipentum entyvio giazo imuran pentasa purinethol rowasa uceris uceris tablets© lialda patient information is supplied by cerner multum inc and lialda consumer information is supplied by first databank inc used under license and subject to their respective copyrights ulcerative colitis slideshow pictures inflammatory bowel disease slideshow pictures take the ulcerative colitis quiz from digestive resources8 ways to control frequent diarrhea should you have surgery how to fight uc flares featured centers how could you live better with migraine not being defined by your cancer track cold  flu in your area health solutions from our sponsors frequent constipation greater food accessibility